Improvements in self‐confidence and satisfaction with self‐injection after introducing self‐injection of dupilumab in patients with atopic dermatitis
Abstract Dupilumab was approved for treating adult patients with atopic dermatitis (AD) refractory to topical therapy in Japan in April 2018, and self‐injection of dupilumab has been available since May 2019. Subcutaneous self‐injection of medication has benefits for patients and the healthcare syst...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Journal of Cutaneous Immunology and Allergy |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cia2.12313 |
| _version_ | 1797326678096084992 |
|---|---|
| author | Makoto Ito Masahiro Kamata Takeko Ishikawa Hideaki Uchida Shoya Suzuki Ryosuke Takeshima Ayu Watanabe Itsumi Mizukawa Shota Egawa Saki Fukaya Kotaro Hayashi Atsuko Fukuyasu Takamitsu Tanaka Yayoi Tada |
| author_facet | Makoto Ito Masahiro Kamata Takeko Ishikawa Hideaki Uchida Shoya Suzuki Ryosuke Takeshima Ayu Watanabe Itsumi Mizukawa Shota Egawa Saki Fukaya Kotaro Hayashi Atsuko Fukuyasu Takamitsu Tanaka Yayoi Tada |
| author_sort | Makoto Ito |
| collection | DOAJ |
| description | Abstract Dupilumab was approved for treating adult patients with atopic dermatitis (AD) refractory to topical therapy in Japan in April 2018, and self‐injection of dupilumab has been available since May 2019. Subcutaneous self‐injection of medication has benefits for patients and the healthcare system. However, anxiety about self‐injection, lack of confidence, and the complicated procedure could prevent initiating self‐injection. In this study, we assessed the experience of AD patients treated with dupilumab before and after introducing self‐injection, utilizing the Self‐Injection Assessment Questionnaire (SIAQ). Adult AD patients who received dupilumab by self‐injection and had been treated for more than 3 months after initiating self‐injection in our hospital from March 1, 2020, to June 19, 2021, were included in this study. Patients rated their perceptions about self‐injections using the SIAQ before the first self‐injection and 3 months after initiating self‐injection. Data were collected retrospectively from their charts. Data on 36 patients were analyzed. The mean age was 34.1 ± 11.5 years. Twenty patients used a prefilled auto‐injector, and the others used a prefilled syringe. Scores on self‐confidence and satisfaction with self‐injection significantly improved after introducing self‐injection. Feelings about injections improved in patients over 40 years and in those who felt anxious about self‐injection. A strong correlation in scores between satisfaction with self‐injection and the ease of use was observed. The results were not affected by clinical severity, gender, or device. Our results could encourage patients who dither to introduce self‐injection of dupilumab due to anxiety and/or lack of self‐confidence about self‐injection to initiate self‐injection. |
| first_indexed | 2024-03-08T06:27:41Z |
| format | Article |
| id | doaj.art-bf8f9473143e4fcba7849cbbc62924ca |
| institution | Directory Open Access Journal |
| issn | 2574-4593 |
| language | English |
| last_indexed | 2024-03-08T06:27:41Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Journal of Cutaneous Immunology and Allergy |
| spelling | doaj.art-bf8f9473143e4fcba7849cbbc62924ca2024-02-03T13:30:22ZengFrontiers Media S.A.Journal of Cutaneous Immunology and Allergy2574-45932023-10-016515215810.1002/cia2.12313Improvements in self‐confidence and satisfaction with self‐injection after introducing self‐injection of dupilumab in patients with atopic dermatitisMakoto Ito0Masahiro Kamata1Takeko Ishikawa2Hideaki Uchida3Shoya Suzuki4Ryosuke Takeshima5Ayu Watanabe6Itsumi Mizukawa7Shota Egawa8Saki Fukaya9Kotaro Hayashi10Atsuko Fukuyasu11Takamitsu Tanaka12Yayoi Tada13Department of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanAbstract Dupilumab was approved for treating adult patients with atopic dermatitis (AD) refractory to topical therapy in Japan in April 2018, and self‐injection of dupilumab has been available since May 2019. Subcutaneous self‐injection of medication has benefits for patients and the healthcare system. However, anxiety about self‐injection, lack of confidence, and the complicated procedure could prevent initiating self‐injection. In this study, we assessed the experience of AD patients treated with dupilumab before and after introducing self‐injection, utilizing the Self‐Injection Assessment Questionnaire (SIAQ). Adult AD patients who received dupilumab by self‐injection and had been treated for more than 3 months after initiating self‐injection in our hospital from March 1, 2020, to June 19, 2021, were included in this study. Patients rated their perceptions about self‐injections using the SIAQ before the first self‐injection and 3 months after initiating self‐injection. Data were collected retrospectively from their charts. Data on 36 patients were analyzed. The mean age was 34.1 ± 11.5 years. Twenty patients used a prefilled auto‐injector, and the others used a prefilled syringe. Scores on self‐confidence and satisfaction with self‐injection significantly improved after introducing self‐injection. Feelings about injections improved in patients over 40 years and in those who felt anxious about self‐injection. A strong correlation in scores between satisfaction with self‐injection and the ease of use was observed. The results were not affected by clinical severity, gender, or device. Our results could encourage patients who dither to introduce self‐injection of dupilumab due to anxiety and/or lack of self‐confidence about self‐injection to initiate self‐injection.https://doi.org/10.1002/cia2.12313atopic dermatitisdupilumabSelf‐Injection Assessment Questionnaire |
| spellingShingle | Makoto Ito Masahiro Kamata Takeko Ishikawa Hideaki Uchida Shoya Suzuki Ryosuke Takeshima Ayu Watanabe Itsumi Mizukawa Shota Egawa Saki Fukaya Kotaro Hayashi Atsuko Fukuyasu Takamitsu Tanaka Yayoi Tada Improvements in self‐confidence and satisfaction with self‐injection after introducing self‐injection of dupilumab in patients with atopic dermatitis Journal of Cutaneous Immunology and Allergy atopic dermatitis dupilumab Self‐Injection Assessment Questionnaire |
| title | Improvements in self‐confidence and satisfaction with self‐injection after introducing self‐injection of dupilumab in patients with atopic dermatitis |
| title_full | Improvements in self‐confidence and satisfaction with self‐injection after introducing self‐injection of dupilumab in patients with atopic dermatitis |
| title_fullStr | Improvements in self‐confidence and satisfaction with self‐injection after introducing self‐injection of dupilumab in patients with atopic dermatitis |
| title_full_unstemmed | Improvements in self‐confidence and satisfaction with self‐injection after introducing self‐injection of dupilumab in patients with atopic dermatitis |
| title_short | Improvements in self‐confidence and satisfaction with self‐injection after introducing self‐injection of dupilumab in patients with atopic dermatitis |
| title_sort | improvements in self confidence and satisfaction with self injection after introducing self injection of dupilumab in patients with atopic dermatitis |
| topic | atopic dermatitis dupilumab Self‐Injection Assessment Questionnaire |
| url | https://doi.org/10.1002/cia2.12313 |
| work_keys_str_mv | AT makotoito improvementsinselfconfidenceandsatisfactionwithselfinjectionafterintroducingselfinjectionofdupilumabinpatientswithatopicdermatitis AT masahirokamata improvementsinselfconfidenceandsatisfactionwithselfinjectionafterintroducingselfinjectionofdupilumabinpatientswithatopicdermatitis AT takekoishikawa improvementsinselfconfidenceandsatisfactionwithselfinjectionafterintroducingselfinjectionofdupilumabinpatientswithatopicdermatitis AT hideakiuchida improvementsinselfconfidenceandsatisfactionwithselfinjectionafterintroducingselfinjectionofdupilumabinpatientswithatopicdermatitis AT shoyasuzuki improvementsinselfconfidenceandsatisfactionwithselfinjectionafterintroducingselfinjectionofdupilumabinpatientswithatopicdermatitis AT ryosuketakeshima improvementsinselfconfidenceandsatisfactionwithselfinjectionafterintroducingselfinjectionofdupilumabinpatientswithatopicdermatitis AT ayuwatanabe improvementsinselfconfidenceandsatisfactionwithselfinjectionafterintroducingselfinjectionofdupilumabinpatientswithatopicdermatitis AT itsumimizukawa improvementsinselfconfidenceandsatisfactionwithselfinjectionafterintroducingselfinjectionofdupilumabinpatientswithatopicdermatitis AT shotaegawa improvementsinselfconfidenceandsatisfactionwithselfinjectionafterintroducingselfinjectionofdupilumabinpatientswithatopicdermatitis AT sakifukaya improvementsinselfconfidenceandsatisfactionwithselfinjectionafterintroducingselfinjectionofdupilumabinpatientswithatopicdermatitis AT kotarohayashi improvementsinselfconfidenceandsatisfactionwithselfinjectionafterintroducingselfinjectionofdupilumabinpatientswithatopicdermatitis AT atsukofukuyasu improvementsinselfconfidenceandsatisfactionwithselfinjectionafterintroducingselfinjectionofdupilumabinpatientswithatopicdermatitis AT takamitsutanaka improvementsinselfconfidenceandsatisfactionwithselfinjectionafterintroducingselfinjectionofdupilumabinpatientswithatopicdermatitis AT yayoitada improvementsinselfconfidenceandsatisfactionwithselfinjectionafterintroducingselfinjectionofdupilumabinpatientswithatopicdermatitis |